Related Experiment Videos
[Clinico-morphological changes in ectropion after treatment with polydeoxyribonucleotide (PDRN)]
I De Luca Brunori1, M Urbano, L Romani
1Istituto di Clinica Ostetrica e Ginecologia, Università di Pisa.
Annali Di Ostetricia, Ginecologia, Medicina Perinatale
|November 1, 1990
Summary
Polydeoxyribonucleotide (PDRN) vaginal suppositories effectively treated cervical ectropion in women. The treatment reduced symptoms, inflammation, and improved vaginal health and immune balance.
Area of Science:
- Gynecology
- Immunology
- Cell Biology
Background:
- Cervical ectropion is a common condition affecting women of fertile age.
- Current treatments may have limitations, necessitating exploration of novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of Polydeoxyribonucleotide (PDRN) vaginal suppositories for treating cervical ectropion.
- To assess PDRN's impact on local symptomatology, vaginal cytology, colposcopic findings, and immune response.
Main Methods:
- A study involving thirty patients of fertile age with cervical ectropion.
- Treatment administered: Polydeoxyribonucleotide (PDRN) vaginal suppositories for 24 days, with no other concurrent therapies.
- Evaluated parameters included symptomatology, tolerability, vaginal cytology, colposcopy, and bioptic sampling for immune response analysis.
Main Results:
- Significant reduction in subjective symptomatology and average symptom scores.
- Excellent or good tolerability and acceptability reported by patients.
- Observed reduction in inflammation, increased iodine-staining areas, and restoration of balanced T- and B-lymphocyte populations.
Conclusions:
- Polydeoxyribonucleotide (PDRN) demonstrates efficacy in treating cervical ectropion.
- PDRN treatment leads to symptomatic relief, reduced inflammation, and improved vaginal immune homeostasis.